Trontinemab

Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-κ antibody, targeting to Aβ plaques and transferrin receptor 1 (TFR1) . Trontinemab binds to fibrillar Aβ as well as Aβ plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and human TFR1[1][2][3][4].

Product Specifications

CAS Number

[2568868-35-7]

Product Name Alternative

RG6102; RO-7126209

UNSPSC

12352203

Target

Amyloid-β

Type

Inhibitory Antibodies

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/trontinemab.html

Purity

99.90

Solubility

10 mM in DMSO|H2O

Smiles

[Trontinemab]

Molecular Weight

(194.25 kDa)

References & Citations

[1]Trontinemab. IMGT/mAb-DB.|[2]Neațu M, et al. Monoclonal Antibody Therapy in Alzheimer's Disease. Pharmaceutics. 2023 Dec 29;16 (1) :60. |[3]Weber F, et al. Brain Shuttle Antibody for Alzheimer's Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode. Cell Rep. 2018 Jan 2;22 (1) :149-162.|[4]Roche H L. Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants with Prodromal or Mild to Moderate Alzheimer’s Disease[J]. ClinicalTrialsgov Identifier: NCT04639050, 2021, 2024.